Last reviewed · How we verify
NCT04417920
Express Implant Versus Trabeculectomy After Late Failure Trabeculectomy
NA trial testing Express implant device in Glaucoma in 28 participants. Completed in 20 May 2020.
1 May 2019
Quick facts
| Lead sponsor | Menoufia University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 1 July 2017 |
| Primary completion | 1 May 2019 |
| Estimated completion | 20 May 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Express implant device
Conditions studied
- Glaucoma — all drugs for Glaucoma →
Sponsor
Menoufia University
Who can join
Adults 42 to 55, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare between outcome of Express implant and subscleral trabeculectomy (SST) in management of glaucoma after previous trabeculectomy with a fibrotic bleb.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Device-modified trabeculectomy for glaucoma.
Park J, Rittiphairoj T, Wang X, E JY, et al · · 2023 · cited 6× · PMID 36912740 · DOI 10.1002/14651858.cd010472.pub3 -
An Ex-Press implant versus trabeculectomy in a fibrotic bleb with late failure after previous trabeculectomy.
Wagdy F, Mokbel TH, Elsorogy H, Alnagdy A, et al · · 2021 · cited 2× · PMID 33747813 · DOI 10.18240/ijo.2021.03.08
Verify or expand the search:
- PubMed search for NCT04417920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glaucoma
Currently open trials in the same condition.
- NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
- NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
- NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
- NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
- NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting
Other Menoufia University trials
Trials by the same sponsor.
- NCT07522671 — Clinical Performance of 3D-Printed Resin and Zirconia Implant Restorations · NA · recruiting
- NCT07516236 — Dynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock · not yet recruiting
- NCT07485517 — Deep Versus Moderate Neuromuscular Blocking · NA · recruiting
- NCT07506044 — Dexmedetomidine as an Adjuvant During Dural Puncture Epidural · NA · recruiting
- NCT07322471 — Efficacy and Safety of Flexible Ureteroscopy Versus Percutaneous Nephrolithotomy in Management of Staghorn Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04417920 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Menoufia University
- Last refreshed: 5 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04417920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing